Immutep (IMMP) Non-Current Assets (2011 - 2026)
Immutep's (IMMP) quarterly Non-Current Assets came in at $1.9 million in Q2 2026, down 62.9% on a YoY basis from $5.1 million in Q2 2025, and down 61.51% quarter-over-quarter from $4.9 million in Q4 2025.
Analysis
Immutep (IMMP) Non-Current Assets (2011 - 2026) Analysis & Trends
Immutep (IMMP) has reported Non-Current Assets for 16 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Assets fell 62.9% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 million (down 62.9% YoY), and the FY2026 full-year result was $1.9 million, down 62.9% from the prior year.
- Non-Current Assets retreated to $1.9 million in Q2 2026 per IMMP's latest filing, from $4.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $8.3 million in Q2 2023 and bottomed at $1.9 million in Q2 2026.
- Historically, Non-Current Assets has averaged $6.1 million across 5 years, with a median of $6.7 million in 2024.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets climbed 2.56% in 2023, then sank 62.9% in 2026.
- Over 5 years, Non-Current Assets stood at $7.1 million in 2022, then dropped by 1.29% to $7.0 million in 2023, then dropped by 19.98% to $5.6 million in 2024, then decreased by 13.08% to $4.9 million in 2025, then plunged by 61.51% to $1.9 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.9 million, $4.9 million, and $5.1 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Immutep | 51.68 Mn | 51.68 Mn | - | 1.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.87 Mn |
| Dec 31, 2025 | 4.87 Mn |
| Jun 30, 2025 | 5.05 Mn |
| Dec 31, 2024 | 5.60 Mn |
| Jun 30, 2024 | 6.74 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Jun 30, 2023 | 8.34 Mn |
| Dec 31, 2022 | 7.09 Mn |
| Jun 30, 2022 | 8.14 Mn |
| Dec 31, 2021 | 9.15 Mn |
| Jun 30, 2021 | 10.48 Mn |
| Dec 31, 2020 | 10.38 Mn |
| Jun 30, 2020 | 10.12 Mn |
| Dec 31, 2019 | 11.00 Mn |
| Jun 30, 2019 | 11.91 Mn |
| Jun 30, 2018 | 13.90 Mn |
| Dec 31, 2017 | 14.40 Mn |
| Jun 30, 2017 | 14.31 Mn |
| Mar 31, 2017 | 13.87 Mn |
| Dec 31, 2016 | 19.50 Mn |